InNexus Biotechnology Inc, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, announced that it has received patent grants in Germany, Spain, France, Great Britain and Italy further expanding patent protection of its DXL technology in Europe.

 

The patents, titled 'Method of affinity cross-linking biologically active, immunogenic peptides to antibodies,' relate to the company's ability to create, develop and manufacture antibodies based on its DXL technology platform. The new patents name InNexus scientists as inventors and are solely owned by InNexus.

"These patent grants demonstrate our commitment to providing real value to our shareholders by protecting and ensuring exclusivity of our DXL technology. Our patent portfolio provides potential for future royalty and licensing deals or outright sales of our expanding and maturing family of DXL preclinical candidates," said Jeff Morhet, chairman and CEO of InNexus. "Patents are the currency of our industry and these patent grants also provide InNexus with additional tools to prevent others from making, using and selling DXL antibodies."

CEO Morhet will present at the 7th Annual BIO Investor Forum on October 30, 2008 and his thirty-minute presentation to potential investors and industry partners will begin at 3:15PM within the Twin Peaks South Room of the Palace Hotel in San Francisco, California. He will provide a company overview, including information about InNexus' unique business strategy, its DXL technology platform, partnerships, company milestones and the recent European patent grants.

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.